Drug intelligence / Profile preview

iDAP

Development stage: Phase 1
Lead developer: The First Affiliated Hospital of USTC
Modality: Stem Cell Therapies → Cell Therapies
Administration: Injection

Overview

iDAP is an allogeneic cell therapy consisting of dopaminergic neural precursor cells, likely derived from induced pluripotent stem cells (iPSCs). It is being developed for the treatment of Parkinson's disease (PD). The therapy involves the bilateral implantation of these cells, aiming to replace or augment the degenerated dopamine-producing neurons in the brain, thereby restoring dopaminergic function and improving motor symptoms associated with PD. Clinical trials are evaluating its safety, tolerability, and preliminary efficacy in patients with Parkinson's disease.

Beyond the preview

Go deeper on iDAP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iDAP.

Explore the full profile